logo

WO2016187508A2 Shared neoantigens Google Patents

If you want to confirm some technical details before you order,
just need to send a message or e-mail: [email protected].
Then our professional sales staff will contact you within 2 hours.

WO2016187508A2 - Shared neoantigens - Google Paten

Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises ...

Effective screening of T cells recognizing neoantigens and .

Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells Article (PDF Available) in Oncotarget 9(13) · January 2018 with 261 Reads

Identification of Glycopeptides as Posttranslationally .

Leukemias are highly immunogenic, but they have a low mutational load, providing few mutated peptide targets. Thus, the identification of alternative neoantigens is a pressing need. Here, we identify 36 MHC class I–associated peptide antigens with O-linked β- N -acetylglucosamine ( O -GlcNAc) modifications as candidate neoantigens, using three experimental approaches.

WO2016187508A2 - Shared neoantigens - Google Paten

Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises ...

Genomic analysis of 63,220 tumors reveals insights into .

Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Ryan J. Hartmaier 1 ... Identification of shared neoantigens for non-individualized targeted cancer immunotherapies ... and JuC receive salary and have ownership interest (including patents) in Foundation Medicine. JeC and WP ...

WO2016187508A2 - Shared neoantigens - Google Paten

Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises ...

Endogenous CD4+ T Cells Recognize Neoantigens in Lung .

T cells specific for neoantigens encoded by mutated genes in cancers are increasingly recognized as mediators of tumor destruction after immune-checkpoint inhibitor therapy or adoptive cell transfer. Much of the focus has been on identifying epitopes presented to CD8+ T cells by class I MHC. However, CD4+ class II MHC-restricted T cells have been shown to have an important role in antitumor ...

Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccin

Somatic mutations binding to the patient's MHC and recognized by autologous T cells (neoepitopes) are ideal cancer vaccine targets. They combine a favorable safety profile due to a lack of expression in healthy tissues with a high likelihood of immunogenicity, as T cells recognizing neoepitopes are not shaped by central immune tolerance.

Genomic analysis of 63,220 tumors reveals insights into .

Methods. A cancer gene-focused, hybrid capture-based genomic analysis was performed on 63,220 unique tumors. Neoantigens were predicted using a combined peptide processing and MHC-I binding prediction tool (IEDB) for all recurrent (>10 tumors) missense alterations and non-frameshift indels for the two most common HLA-A/B subtypes in North American/European populations.

WO2016187508A3 - Shared neoantigens - Google Paten

WO2016187508A3 - Shared neoantigens - Google Patents Shared neoantigens Download PDF Info Publication number ... WO2016187508A2 (en Inventor Edward F. Fritsch Nir Hacohen Michael Steven ROONEY Sachet Ashok SHUKLA Original Assignee The Broad Institute Inc. Dana-Farber Cancer Institute, Inc.

Evolution of Neoantigen Landscape during Immune Checkpoint .

Introduction. Tumor cells contain nonsynonymous somatic mutations that alter the amino acid sequences of the proteins encoded by the affected genes ().Those alterations are foreign to the immune system and may therefore represent tumor-specific neoantigens capable of inducing antitumor immune responses ().Somatic mutational and neoantigen density has recently been shown to correlate with long ...

Multi-omics discovery of exome-derived neoantigens in .

Although mutated HLA ligands are considered ideal cancer-specific immunotherapy targets, evidence for their presentation is lacking in hepatocellular carcinomas (HCCs). Employing a unique multi-omics approach comprising a neoepitope identification pipeline, we assessed exome-derived mutations naturally presented as HLA class I ligands in HCCs.